1   **Supplementary Table S7.** Summary of clinical response and disease control rates of patients

2   with advanced solid tumors treated with botensilimab monotherapy or botensilimab in combination

3   with balstilimab.

Variable	Botensilimab monotherapy (N=64)	Botensilimab + Balstilimab (N=147)	Prior αPD-(L)1/-CTLA-4 (N=63)	ICI Naïve (N= 148)	All Patients (N=211)
Objective Response Rate for confirmed responses					
n (%)	4 (6.3)	24 (16.3)	10 (15.9)	18 (12.2)	28 (13.3)
95% CI	(1.7, 15.2)	(10.7, 23.3)	(7.9, 27.3)	(7.4, 18.5)	(9.0, 18.6)
Best Overall Response by RECIST v1.1 for confirmed responses, n (%)					
Complete Response	1 (1.6)	1 (0.7)	1 (1.6)	1 (0.7)	2 (0.9)
Partial Response	3 (4.7)	23 (15.7)	9 (14.3)	17 (11.5)	26 (12.3)
Stable Disease	25 (39.1)	56 (38.1)	28 (44.4)	53 (35.8)	81 (38.4)
Progressive Disease	31 (48.4)	62 (42.2)	23 (36.5)	70 (47.3)	93 (44.1)
Not evaluable	0	1 (0.7)	0	1 (0.7)	1 (0.5)
Not Available	4 (6.3)	4 (2.7)	2 (3.2)	6 (4.1)	8 (3.8)
Disease Control Rate (CR, PR, SD6+)					
n (%)	29 (45.3)	80 (54.4)	38 (60.3)	71 (48.0)	109 (51.7)
95% CI	(32.8, 58.3)	(46.0, 62.6)	(47.2, 72.4)	(39.7, 56.3)	(44.7, 58.6)
Disease Control Rate (CR, PR, SD12+)					
n (%)	18 (28.1)	64 (43.5)	27 (42.9)	55 (37.2)	82 (38.9)
95% CI	(17.6, 40.8)	(35.4, 52.0)	(30.5, 56.0)	(29.4, 45.5)	(32.2, 45.8)
Disease Control Rate (CR, PR, SD24+)					
n (%)	6 (9.4)	36 (24.5)	17 (27.0)	25 (16.9)	42 (19.9)
95% CI	(3.5, 19.3)	(17.8, 32.3)	(16.6, 39.7)	(11.2, 23.9)	(14.7, 25.9)
Median follow-up, months					
Median	6.1	6.2	7.4	6.0	6.2
Min, Max	0.7, 34.9	0.6, 34.5	0.7, 34.9	0.6, 34.5	0.6, 34.9

4   Objective Response Rate, proportion of subjects with best overall response of complete response
5   (CR) or partial response (PR). Best overall response is the best response recorded over all on-
6   study time-point assessments recorded before start of a new anti-cancer therapy. Disease control
7   rate, proportion of subjects with confirmed CR, PR, or stable disease (SD) for 6+, 12+ or 24+
8   weeks. Not evaluable: scan done but unevaluable. Not available: no scan or missing assessment.
9   CI; confidence interval.